title: Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma.
abstract: The behaviour of circulating dendritic cells (DCs) and DC generation from monocytes in melanoma patients during the progression of disease have not been described. We report a significant decrease in the absolute number of total DCs, which mainly affects plasmacytoid DCs in stage IV. Additionally, monocyte-DC generation is less efficient in advanced stages, resulting in DCs that exhibit increased phagocytic capacity, potentially indicating a less mature state. These findings elucidate aspects of basic tumour-mediated immunosuppression, which may have implications for immunotherapeutic approaches, suggesting that the selection of patients for immunotherapy should also be made on the basis of their immune status.
authors.affiliation: Department of Clinical and Experimental Medicine, Division of Pediatrics, Laboratory of Immunology, University of Pisa, Pisa, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Failli
authors.forename: Annalisa
authors.initials: A
authors.lastname: Legitimo
authors.forename: Giulia
authors.initials: G
authors.lastname: Orsini
authors.forename: Antonella
authors.initials: A
authors.lastname: Romanini
authors.forename: Rita
authors.initials: R
authors.lastname: Consolini
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002452:Cell Count; D048430:Cell Shape; D002478:Cells, Cultured; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D003911:Dextrans / Q000378:metabolism; D018450:Disease Progression; D015536:Down-Regulation; D004705:Endocytosis; D005260:Female; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D037181:Lectins, C-Type / Q000378:metabolism; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins / Q000378:metabolism; D008545:Melanoma / Q000276:immunology* / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D009367:Neoplasm Staging; D010587:Phagocytosis; D010641:Phenotype; D011956:Receptors, Cell Surface / Q000378:metabolism; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D019139:Tumor Escape
chemical_list: D003911:Dextrans; D037181:Lectins, C-Type; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D011956:Receptors, Cell Surface; C015219:fluorescein isothiocyanate dextran; D016650:Fluorescein-5-isothiocyanate
keywords: Circulating dendritic cells; Generation of dendritic cells; Immunotherapy; Melanoma